NextBio

Help
Description: A direct-acting vasodilator that is used as an antihypertensive agent. [PubChem]
Drug Type: Small Molecule; Approved
Pharmacology: A vasodilator, hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. It is commonly used in the condition of pregnancy called preeclampsia.
Mechanism of Action: Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. Hydralazine, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.
Indication: For the treatment of essential hypertension, alone or as an adjunct. Also for the management of moderate to severe hypertension, congestive heart failure, and hypertension secondary to pre-eclampsia/eclampsia.
Half Life: 3 to 7 hours
View Complete Description



Data Correlations | 3 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
CA3 100 100
PON1 97 97
ID3 93 93
CYP2E1 89 89
ARG1 89 89
GK 86 86
View Top Genes
Biogroups category icon Biogroups
Score Help
Tight Junction 100 100
Voltage-dependent potassium channel 99 99
GA13 Pathway 99 99
Spectrin repeat 99 99
Sprouty Regulation of Ryrosine Kina… 98 98
Cytokine Cytokine Receptor Interact… 97 97
View Top Biogroups

Individual Studies

  • Breast tumor biopsies before and after hydralazine and valproate treatment

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    Core-needle biopsies were taken before and after patients received for 7 days hydralazine and valproate (before receiving the first course of chemotherapy).

    Authors: Perez-Plasencia Carlos, Arce Claudia, Duenas-Gonzalez Alfonso

    Organization: INSTITUTO NACIONAL DE CANCEROLOGIA BASIC…

  • Liver Pharmacology and Xenobiotic Response Repertoire

    Rattus norvegicus Rattus norvegicus | RNA Expression   RNA Expression

    A definition of RNA expression changes that correlate with liver response programs and an understanding of the similarities and differences in responses to different classes of chemicals would aid in new chemical or drug characterization and add to our understanding of liver biology.

    Authors: Natsoulis G, Pearson CI, Gollub J et al.

    Organization: Iconix Biosciences 325 E. Middlefield Rd…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving hydralazine.

View All Author iconAuthors
  • Daniel Henrion
  • Laurent Loufrani
  • Michael L Sabolinski
  • S William Tam
  • Manuel Worcel
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • National Institute of Cancerología
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Arkansas
  • Hoffmann-La Roche
  • The George Institute
View All Affiliations icon Organizations
  • Purdue University
  • Université d'Angers
  • University of Minnesota
  • University of Adelaide
  • Boston University School of Medicine

Clinical Trials | 67 trials

Help for Clinical Trials View All

© 2010 NextBio